N/A N=51 Effect of Healing Touch on the Experience of Women Undergoing Treatment for Breast Cancer
Breast Cancer
Primary: FACT-B Quality of Life Score — 91.9 score on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=187 Utilizing Protein During Weight Loss to Impact Physical Function and Bone
Obesity · Weight Loss · Diet Modification
Primary: 18-month Change From Baseline in Total Hip Trabecular Volumetric Bone Mineral Density Assessed by Computed Tomography (CT) in mg/cm^3 — -0.91; -1.77; -0.03 mg/cm^3…
Phase 3 N=302 Immunogenicity, Safety and Interchangeability of Two Tbe Vaccines Administered According to a Conventional Schedule in Children
Encephalitis, Tick-Borne
Primary: Seropositivity Rate as Determined by Neutralization Test (NT) 28 Days After the Second Vaccination — 100; 97.8 Percentage of participants — p=<0.001
Phase 2 N=110 A Proof-of-principle Clinical Study Investigating the Efficacy of an Experimental Dentifrice Containing Sodium Bicarbonate and Sodium Hyaluronate on Gingivitis
Gingivitis
Primary: Number of Bleeding Sites at 6 Weeks (Comparison of Experimental Versus Negative Control Dentifrice) — 9.5; 20.5 Number of Sites — p=<0.0001
Phase 3 N=210 A Study of Tirzepatide (LY3298176) in Chinese Participants Without Type 2 Diabetes Who Have Obesity or Overweight (SURMOUNT-CN)
Obesity · Overweight · Metabolism and Nutrition Disorder
Primary: Mean Percent Change From Baseline in Body Weight — -14.4; -19.9; -2.4 Percent change — p=<0.001
N/A N=117 Human Use Condition Study- Evaluation of Implanted Leads in Humans
Pacemaker Malfunction
Primary: Number of Participants With in Vivo Cyclic Mean Curvature of Pacing and Defibrillation Leads in the Extravenous Region Determined During Specified Arm Movements — 109…
Phase 2 N=18 A Clinical Trial of Retinal Gene Therapy for X-linked Retinitis Pigmentosa Using BIIB112
X-Linked Retinitis Pigmentosa
Primary: Part 1: Number of Participants With Dose-Limiting Toxicities (DLTs) — 0; 0; 0; 0 Participants
Phase 2 N=196 Study of Efficacy and Safety of Novel Spartalizumab Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma
Melanoma
Primary: Overall Response Rate (ORR) — 8.9; 4.7; 4.7; 6.8 Percentage of participants
Phase 3 N=553 A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Macular Edema Secondary to Branch Retinal Vein Occlusion
Macular Edema · Branch Retinal Vein Occlusion
Primary: Part 1: Change From Baseline in Best Corrected Visual Acuity (BCVA) in the Study Eye at Week 24 — 16.9; 17.5 ETDRS Letters — p=0.4978
Phase 3 N=207 Octagam 10% Therapy in COVID-19 Patients With Severe Disease Progression
Covid-19
Primary: Proportion of Subjects Reaching Stabilization or Improvement in Clinical Status at Day 7 — 89; 82 Participants
Phase 3 N=579 Recombinant FSH Investigation in the Treatment of Infertility With Assisted Reproductive Technology (ART) (RITA-1)
Infertility
Primary: Cumulative Ongoing Pregnancy Rate After the Fresh Cycle and Cryopreserved Cycles Initiated Within 12 Months From the Start of COS — 63.0; 0.0 percentage of participants…
Phase 3 N=597 A Therapeutic Equivalence Study in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension
Primary Open Angle Glaucoma · Ocular Hypertension
Primary: Mean Difference in Intraocular Pressure of Both Eyes Between the Two Treatment Groups — 24.92; 25.06; 24.87; 25.12 mmHg
Phase 2 N=174 UH3 Varenicline for Cannabis Use Disorder
Cannabis Use Disorder
Primary: Efficacy of Varenicline vs. Placebo for Reducing Total Number of Weekly Cannabis Use Sessions — 10.3; 11.6; 9.4; 11.7 number of weekly use sessions
Phase 2 N=93 CHP 834 Unrelated and Partially Matched Related Donor Peripheral Stem Cell Transportation for T and B Cell Depletion
Immunodeficiencies
Primary: Number of Participants With Successful Engraftment — 87; 5 Participants
Phase 2 N=22 Use of Trifluridine/Tipiracil and Oxaliplatin as Induction Chemotherapy for the Treatment of Resectable Esophageal or Gastroesophageal Junction (GEJ) Adenocarcinoma
Clinical Stage IIA Esophageal Adenocarcinoma AJCC v8 · Clinical Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8 · Clinical Stage III Esophageal Adenocarcinoma AJCC v8
Primary: Number of Patients With a Pathologic Complete Response — 2 Participants